Genitourinary Cancer [2025] Update: ASCO GU 2025 Highlights with Nataliya Mar, MD MOASC скачать в хорошем качестве

Genitourinary Cancer [2025] Update: ASCO GU 2025 Highlights with Nataliya Mar, MD MOASC

ARTICLE: https://oncologytube.com/genitourinar... In this video, Nataliya Mar, MD - Associate Professor at UC Irvine, presents the updated analyses from ASCOGU 2025, featuring key findings from the Telepro 2, CheckMate 274, and Niagara trials. "Interestingly, both DNA damage repair pathway positive and negative patients seem to have benefited from the addition of telopera to enzalutamide," says Dr. Mar, highlighting breakthroughs in prostate cancer treatment. She also notes, "The updated analysis of CheckMate 274 further confirmed the benefit of adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma," and adds, "Adding immunotherapy early in this patient population leads to increased various outcomes, including a pathologic complete response," regarding the Niagara trial. Learn how these innovative treatments—telopera, nivolumab, and durvalumab—are transforming oncology, with insights into survival data and biomarkers. Don’t miss this expert-led deep dive into the future of cancer care! Subscribe for more updates on cancer research and treatment advancements. Timestamps below for easy navigation! Timestamps: 00:00 - Introduction: Overview of ASCOGU 2025 Trial Updates 00:03 - Telepro 2 Trial Analysis: Benefits of Telopera + Enzalutamide 00:06: DNA Damage Repair Pathway Insights 00:14: Positive vs. Negative Patient Outcomes 00:23: BRCA1/2 and DNA Repair Alterations 00:44 - CheckMate 274 Study Update: Nivolumab in High-Risk Urothelial Carcinoma 00:55: Adjuvant Nivolumab Benefits 01:03: Overall Survival and Disease-Free Survival 01:32: Solidifying Nivolumab’s Role 01:39 - Niagara Trial Insights: Durvalumab in Perioperative MIBC 01:46: Adding Durvalumab to Cisplatin-Based Chemotherapy 02:02: FDA Approval Status and Early Immunotherapy 02:13: Pathologic Complete Response Outcomes 02:37: Biomarkers in Neo-Adjuvant Therapy 02:51 - Biomarker Discussion: Tumor Mutational Burden and PDL1 03:18: Unselected Patients in Niagara Trial 03:27: Early Immunotherapy Correlations 03:35 - Future Directions: Personalizing Care and RNA Data Challenges 03:51: Intensifying Therapy for Subgroups 04:03: Metastatic RCC Frontline Considerations